<p>Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells</p
© 2017 by the authors. The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance...
The results of the ENESTg1 trial confirm the efficacy of imatinib, but not nilotinib, as a first-lin...
The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
<p>Cells were maintained in supplemented medium for 12 h, and then incubated with nilotinib (0∼100 µ...
<p>Figure 5</p> <p>Antitumor activity of nilotinib on GIST and imatinib-resistant GIST cells. Cells ...
Nilotinib inhibits the tyrosine kinase activity of ABL1/BCR-ABL1 and KIT, platelet-derived growth fa...
<p>Nilotinib antitumor activity in GIST xenograft models. (A) Immunohistochemistry staining for KIT ...
<p>(A) Immunohistochemistry staining for KIT in xenograft lines established from human GISTs: GK1X, ...
KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumours (GISTs) showed a response rate to imatini...
Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchimal tumors of the gastrointestin...
Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the gastrointestin...
The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limite...
The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limite...
© 2017 by the authors. The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance...
The results of the ENESTg1 trial confirm the efficacy of imatinib, but not nilotinib, as a first-lin...
The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
Patients diagnosed with advanced gastrointestinal stromal tumours (GISTs) who are resistant or intol...
<p>Cells were maintained in supplemented medium for 12 h, and then incubated with nilotinib (0∼100 µ...
<p>Figure 5</p> <p>Antitumor activity of nilotinib on GIST and imatinib-resistant GIST cells. Cells ...
Nilotinib inhibits the tyrosine kinase activity of ABL1/BCR-ABL1 and KIT, platelet-derived growth fa...
<p>Nilotinib antitumor activity in GIST xenograft models. (A) Immunohistochemistry staining for KIT ...
<p>(A) Immunohistochemistry staining for KIT in xenograft lines established from human GISTs: GK1X, ...
KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumours (GISTs) showed a response rate to imatini...
Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchimal tumors of the gastrointestin...
Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the gastrointestin...
The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limite...
The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limite...
© 2017 by the authors. The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance...
The results of the ENESTg1 trial confirm the efficacy of imatinib, but not nilotinib, as a first-lin...
The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based...
DOI
Add to ORKG